CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2020.
Drug data last refreshed 15h ago · AI intelligence enriched 18h ago
CARBON DIOXIDE, USP is an inhalation gas approved as a radiographic contrast agent that functions through X-ray contrast activity mechanism. It is used to enhance visualization in diagnostic imaging procedures, particularly where alternative contrast agents pose safety risks. The product serves patients requiring non-iodinated, non-barium imaging alternatives.
Product is in peak lifecycle stage with moderate competitive pressure (30/100), suggesting stable commercial operations but potential plateauing of growth opportunities for marketing and sales teams.
X-Ray Contrast Activity
Radiographic Contrast Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CARBON DIOXIDE, USP offers exposure to diagnostic imaging and radiographic contrast markets within a niche, specialized segment. The peak lifecycle stage and moderate safety profile create career opportunities in product management, field sales, and pharmacovigilance, though limited clinical pipeline may constrain advancement pathways in medical development.